IMRX Immuneering Corporation
$4.27▼ -6.56%
Healthcare
Other
After hours
$4.34▲ +1.64%
Sep 11, 7:30 PM ET
Volume 891.7K
Avg Volume (10D) 754.0K
Key Metrics & Fundamentals
Market Cap
$276.26M
P/E Ratio
–
Div Yield
–%
52W Range
3.86 - 10.08
% vs 50 MA
-11.32%
% vs 200 MA
-17.98%
RSI-14
33.4
MACD Histogram
-0.1000
Beta (1Y vs SPY)
1.20
Free Cash Flow
-$16.53M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$18.91M
COGS
–
Operating Exp
$19.00M
Operating Income
-$19.00M
EBIT
-$19.00M
Pretax Income
-$17.27M
Net Income
-$17.27M
EPS (Diluted)
-0.27
Price & Volume History
Loading chart…
Recent News
Immuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib’s Dual Mechanism for Extended Survival
GlobeNewswire · Sep 10, 2026 11:30 AM
Immuneering to Participate in Upcoming Investor Conferences
GlobeNewswire · Sep 3, 2026 8:05 PM
Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients
GlobeNewswire · Aug 26, 2026 9:16 PM
Zillow downgraded, Global Payments upgraded: Wall Street's top analyst calls
The Fly · Aug 6, 2026 1:48 PM
HC Wainwright Initiates Immuneering at Buy With $14 Price Target
MT Newswires · Aug 6, 2026 11:18 AM
Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates
GlobeNewswire · Aug 5, 2026 11:30 AM
Publication in Cancer Research Details Atebimetinib’s Broad, Durable Preclinical Activity and Favorable Tolerability Across RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition
GlobeNewswire · Jul 21, 2026 8:05 PM
Immuneering Corporation Announces Grants of Inducement Awards
GlobeNewswire · Jul 17, 2026 8:05 PM
Immuneering (IMRX) Upgraded to Buy: Here's What You Should Know
Zacks · Jul 15, 2026 4:00 PM
Immuneering Names Andrew Gengos as CFO
MT Newswires · Jun 15, 2026 12:58 PM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See IMRX's money flow as a full page
Social Sentiment
Avg +0.60 · 2 posts
DiscussionFavorite mid-cap biotech with the most upside? (500M–2.5B mkt cap)
r/investing · Dec 22, 2025
Mentioned as a potential investment and a point of discussion.
positive
+0.60
NewsTradeDiscussion$IMRX Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer
r/wallstreetbets · Aug 1, 2024
The post discusses a positive FDA designation and subsequent price increase, indicating bullish sentiment.
positive
+0.60
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.